Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GBT

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

Global Blood Therapeutics logo

About Global Blood Therapeutics Stock (NASDAQ:GBT)

Advanced Chart

Key Stats

Today's Range
$68.49
$68.49
50-Day Range
$68.07
$68.49
52-Week Range
$21.65
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Global Blood Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

GBT MarketRank™: 

Global Blood Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 928th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Global Blood Therapeutics.

  • Earnings Growth

    Earnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.71) to ($3.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Global Blood Therapeutics has a P/B Ratio of 22.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for GBT.
  • Dividend Yield

    Global Blood Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Global Blood Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for GBT.
  • Search Interest

    Only 1 people have searched for GBT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

Global Blood Therapeutics Inc (GBT)
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
GBT Technologies to acquire Nexus Workspaces from CGI
See More Headlines

GBT Stock Analysis - Frequently Asked Questions

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company's revenue for the quarter was up 41.1% compared to the same quarter last year.

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Meta Platforms (META), Intel (INTC), Bristol Myers Squibb (BMY) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/04/2021
Today
7/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GBT
Fax
N/A
Employees
457
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$303.09 million
Net Margins
-137.30%
Pretax Margin
-137.01%

Debt

Sales & Book Value

Annual Sales
$194.75 million
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
22.46

Miscellaneous

Free Float
64,170,000
Market Cap
$4.62 billion
Optionable
Optionable
Beta
0.45

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:GBT) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners